This article reviews the current literature dealing with pathophysiology, diagnostics, bleeding management, and thromboprophylaxis in patients with acute and chronic liver dysfunction.
INTRODUCTION
Irrespective of the underlying condition and the direct cause liver dysfunction/failure in critical care patients is characterized by hyperbilirubinemia (often), hepatic encephalopathy (in severe cases), and coagulopathy (always). The latter is defined by an International Normalized Ratio (INR) >1. 5 . This definition reflects the central role of the liver in hemostasis. However, recent literature has put the impact of a pathological test result on clinical features into question.
COAGULOPATHY IN LIVER DYSFUNCTION
Blood coagulation is based on complex interactions between cells and plasmatic coagulation factors with elaborated feedback mechanisms including amplifying and inhibiting loops. It is best described by the term 'hemostasis', highlighting the sensible equilibrium between procoagulant and anticoagulant factors as well as fibrinolytic and antifibrinolytic mechanisms.
Most of the coagulation factors are synthesized in the liver; hence, in chronic liver disease their levels are decreased. This is particularly true for the vitamin K-dependent procoagulant factors II, VII, IX, and X, as well as for factor V, but also for the vitamin K-dependent anticoagulant factors protein C and protein S, as well as for antithrombin [1 && ]. Notable exceptions are the von Willebrand factor (vWF) and coagulation factor VIII, which are synthesized in the vascular endothelium and compensatorily elevated in patients with liver cirrhosis. On the other hand, the activity of the vWF cleaving enzyme ADAMTS13, a metalloprotease exclusively produced in hepatic stellate cells, is reduced in liver cirrhotic patients. Deficiency of ADAMTS13, particularly in the presence of elevated levels of large vWF multimers, increases platelet microthrombi formation and might result in sinusoidal microcirculatory disturbances and subsequent progression of liver injury, eventually leading to multiorgan failure [2, 3] . A marked imbalance between decreased ADAMTS13 activity and increased production of large vWF multimers has been shown to be closely related to functional liver capacity, hepatic encephalopathy, hepatorenal syndrome, and intractable ascites in advanced liver cirrhosis and may be useful to predict long-term survival of cirrhotic patients [3, 4] . Therefore, some end-stage liver cirrhotic patients reflect conditions similar to thrombotic thrombocytopenic purpura (TTP) [3] . In transplant patients it has been shown that TTP is sometimes linked to cyclosporine A treatment. Here, cyclosporine A reduces the secretion of ADAMTS13 and leads to conformational changes in the protein structure resulting in diminished ADAMTS13 proteolytic activity [5] . Apart from sequestration of platelets in the spleen due to portal hypertension and subsequent hypersplenism [6] [7] [8] this mechanism may substantially contribute to thrombocytopenia in liver cirrhotic patients. Increased platelet adhesion and aggregation due to increased plasma levels of large vWF multimers and decreased ADAMTS13 activity seem to be rebalanced by thrombocytopenia in liver cirrhotic patients. Therefore, platelet transfusion should be restricted to bleeding complications, as it may result in further liver damage and exacerbated portal and portopulmonary hypertension [9] . Furthermore, changes in profibrinolytic and antifibrinolytic drivers have been reported. Here, plasminogen and alpha 2 -antiplasmin levels are decreased and tissue-plasminogen activator and plasminogen activator inhibitor-1 levels are increased simultaneously [1 && ]. Similar, but more pronounced changes of procoagulant and anticoagulant factors are observed in acute liver injury (ALI)/acute liver failure (ALF) [10 & ]. Recently published data report on reduced fibrinolytic activity in ALF as it has also been shown for the early phase of sepsis [11,12,13 && ]. Taken together, blood coagulation in liver dysfunction is rebalanced, even though on a lower level prone to tipping to thrombosis or hemorrhage depending on concomitant risk factors (Fig. 1) .
COAGULATION TESTS IN LIVER DYSFUNCTION
For comprehension of the concept of balanced blood coagulation in liver dysfunction, knowledge about the scopes and limits of (the more or less routine) coagulation tests performed in the laboratory or at the point-of-care (POC) is essential.
Routine coagulation tests
The basic idea of the prothrombin time (PT), first described in 1935, was monitoring of vitamin K-antagonists (VKA) [14] . In short, the test proceeds as follows: thromboplastins of different origin are added to recalcified citrated plasma and the time until coagulation starts is measured. This procedure only mirrors the amount of procoagulant factors in plasma, but is not capable of measuring vitamin K-dependent anticoagulants (protein C and S) and the complex interaction of cells and coagulation factors in whole blood [ bleeding after trauma or surgery, and also for definition of coagulopathy in liver disease. Meanwhile, it has been shown that the correlation between INR and bleeding tendency in patients scheduled for surgery is poor [15] , which applies to patients with liver dysfunction as well [1
In particular, no correlation could be observed between PT and the bleeding time observed directly on the liver during laparoscopic liver biopsy [17] . However, the validity of INR as a prognostic parameter in liver dysfunction is not affected by this finding [16 & ].
Thrombin generation assays
Thrombin generation assays are special laboratory coagulation tests, measuring the endogenous thrombin potential by at least adding phosopholipids and thromboplastin to platelet poor plasma. The main parameters are lag time, velocity, and area under the reaction curve. 'Basic' thrombin generation is decreased in patients with liver disease. However, as the imbalance between procoagulant and anticoagulant activity in patients with cirrhosis is based on increased factor VIII and decreased protein C it can be detected by thrombin generation assays performed in the presence and absence of soluble thrombomodulin [1 && ,17,18] . The thrombin-thrombomodulin complex is essential to activate the vitamin K-dependent anticoagulative protein C system [1 && ]. In the presence of soluble thrombomodulin thrombin generation test results in patients with acute and chronic liver disease were indistinguishable from those in healthy volunteers or may even be higher [1 && ,13 && ,19]. Similar results can be achieved by the addition of Protac (Pentapharm, Basel, Switzerland), a snake venom that activates protein C in a manner similar to thrombomodulin [10 & ,18,20-22] . Furthermore, the results of thrombin generation assays are modified by the presence and absence of platelets [23] . Notably, platelet factor 4 modulates the substrate specificity of the thrombin-thrombomodulin complex by selectively enhancing protein C activation, while inhibiting thrombin-activatable fibrinolysis inhibitor (TAFI) activation [24] . Altogether, modified thrombin generation assays can be useful for determination of coagulation function in patients with liver dysfunction, but have the major drawback of not being available as routine laboratory tests.
Thrombelastography/rotational thromboelastometry
Viscoelastic tests like thrombelastography and rotational thromboelastometry (ROTEM) are performed in whole blood, mirroring the interaction between platelets and coagulation factors and, above all, the strength and stability of the clot. Here, early values of clot firmness [e.g. amplitude after 5-10 min (A5, A10)] allow for fast and reliable prediction of thromboelastometric maximum clot firmness in patients with hypocoagulability, normocoagulability, and hypercoagulability, and therefore can be used to guide hemostatic therapy in severe bleeding including patients undergoing liver transplantation [25] . ], further challenging the concept of bleeding tendency in liver dysfunction. Notably, hypercoagulability seems to be better detected by whole blood thromboelastometry compared with thrombin generation tests using platelet poor plasma [32] .
BLEEDING MANAGEMENT IN LIVER DYSFUNCTION AND LIVER TRANSPLANTATION
Following the concept of balanced hemostasis in liver dysfunction application of blood products and coagulation factors in order to correct laboratory values (e.g., prior to interventions) is not appropri-
]. Nevertheless, fresh frozen plasma (FFP) and platelet transfusion are still used for preprocedural prophylaxis in cirrhosis patients [34, 35] and liver dysfunction is one of the factors associated with greater use of prophylactic plasma transfusion in the United Kingdom [36] . However, a high proportion of current FFP transfusion are of unproven clinical benefit and have to be considered as inappropriate [37 & ,38 & ]. In severe bleeding FFP transfusion is often recommended but has to be assessed critically regarding its risks and benefits [39, 40] . For correction of coagulopathy high amounts of FFP have to be applied, which often results in increased portal pressure and subsequently leads to increased bleeding and acute lung injury due to transfusionassociated circulatory overload. Therefore, intravenous fluid restriction rather than prophylactic administration of large volumes of FFP is recommended in patients with gastrointestinal bleeding or undergoing major liver surgery [41] . Moreover, transfusion-related acute lung injury, immunomodulation, increased nosocomial infection rates, and last but not least delay of therapy due to the thawing process have to be considered for the use of FFP [42] . . However, platelet transfusion has been shown to be associated with a significant reduction in 1-year survival (74 vs. 92%; P < 0.001) in liver transplantation, independent of whether the platelet count was below or above 50/nl before platelet transfusion [49] . Cryoprecipitate, containing fibrinogen and factor XIII but also vWF and factor VIII, would further increase the already high levels of vWF and factor VIII possibly contributing to a procoagulant switch with subsequent thrombosis [50] . Pharmacologic agents such as antifibrinolytic drugs (e.g. tranexamic acid) or activated recombinant factor VII (rFVIIa) may be indicated in selected individuals, but these agents do not have a routine role in the management of patients with liver cirrhosis or undergoing liver surgery [41, 
VENOUS THROMBOEMBOLISM IN LIVER DYSFUNCTION
In line with the above described observations patients with liver dysfunction are not 'autoanticoagulated' [ [58, 59] .
VENOUS THROMBOPROPHYLAXIS IN PATIENTS WITH LIVER DYSFUNCTION
Basically, VTE prophylaxis can be performed by pharmacological and/or mechanical means (compression stockings, intermittent pneumatic compression) [60] . The so-called American College of Chest Physicians guidelines are updated every 4 years and present and grade the available evidence regarding thrombosis and thromboprophylaxis. Interestingly, these comprehensive guidelines do not offer any recommendation for VTE prophylaxis in patients with liver disease. This might be due to the lacking evidence, as in most studies dealing with thromboprophylaxis, patients with liver dysfunction are excluded. One recent study investigating the prevention of portal vein thrombosis in patients with chronic liver disease proved efficacy and safety of enoxaparin application (4000 U subcutaneously once daily) in cirrhotic patients [61 & ]. Early anticoagulation treatment in cirrhotic and noncirrhotic patients with portal vein thrombosis and acute variceal bleeding resulted in a satisfactory rate of recanalization with minimal procedure-associated morbidity [62, 63] . Prophylactic use of low molecular weight heparin (LMWH) in patients with cirrhosis appears to be well tolerated [64 & ]. A decreased anti-Xa value in cirrhotic patients and a negative correlation with liver function challenge the unconditional use of anti-Xa assays in LMWH monitoring in cirrhotic patients and reveal a potential limitation of anti-Xa analysis in these patients. Low levels of antithrombin, because of reduced hepatic synthesis, are the most likely cause of this phenomenon [64 & ]. As argatroban is mainly metabolized in the liver it should be used with caution in patients with liver dysfunction [65] and/or hyperbilirubinemia [66] . Despite some absolute contraindications (e.g., peripheral vascular disease) mechanical DVT prophylaxis can be used in most patients, and is of particular benefit in patients with suspected bleeding risk. Nevertheless, mechanical DVT prophylaxis is used only in the minority of patients in the ICU [67] .
CONCLUSION
Coagulopathy in patients with critical liver dysfunction is complex and can quickly decompensate to bleeding as well as to thrombosis. Both are associated with worse outcome. However, routine plasmatic coagulation tests such as PT and INR are not able to discriminate between hypo-and hypercoagulability and are not able to predict the risk of bleeding in patients with liver dysfunction. Therefore, prophylactic transfusion of FFP and platelets due to an increased INR should be avoided in this patient population, and hemostatic interventions should only be performed in case of clinically relevant bleeding. In contrast, thrombin generation assays in the presence and absence of thrombomodulin or Protac, a snake venom that activates protein C in a manner similar to thrombomodulin, as well as viscoelastic tests (thrombelastography/thromboelastometry) indicate that patients with liver dysfunction are rather hypercoagulable with the inherent risk of thrombosis. Notably, patients with liver dysfunction and increased INR are not 'autoanticoagulated'. Therefore, thromboprophylaxis should strongly be considered in patients with liver dysfunction. The authors conclude that care should be taken to avoid excessive substitution with PCC, however, an accurate monitoring of patients' coagulation status may allow thrombotic risks to be reduced.
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